[
  {
    "ts": null,
    "headline": "GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm",
    "summary": "The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. for violations of the securities...",
    "url": "https://finnhub.io/api/news?id=4b35da5450e8215abaa504c8eb6d0c5098f4cf1e29c68b372e1823072ee2de06",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752520144,
      "headline": "GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm",
      "id": 135931481,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. for violations of the securities...",
      "url": "https://finnhub.io/api/news?id=4b35da5450e8215abaa504c8eb6d0c5098f4cf1e29c68b372e1823072ee2de06"
    }
  },
  {
    "ts": null,
    "headline": "WHO endorses Gilead’s Yeztugo for HIV prevention",
    "summary": "The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.",
    "url": "https://finnhub.io/api/news?id=096cf34967ce17763fa879d2e7057dfc540f68921d2008ba90669f61b4572eaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752507981,
      "headline": "WHO endorses Gilead’s Yeztugo for HIV prevention",
      "id": 135937101,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.",
      "url": "https://finnhub.io/api/news?id=096cf34967ce17763fa879d2e7057dfc540f68921d2008ba90669f61b4572eaf"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025",
    "summary": "FOSTER CITY, Calif., July 14, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo®) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention, including pregnant and lactating women, adolescents and young people, and supports lenacapavir dosing recommendations for peopl",
    "url": "https://finnhub.io/api/news?id=63c7187af8f8050b9f2c5293064471c6f77833a43dcbe715d36e6ca41d95f138",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752499800,
      "headline": "Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025",
      "id": 135927740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., July 14, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo®) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention, including pregnant and lactating women, adolescents and young people, and supports lenacapavir dosing recommendations for peopl",
      "url": "https://finnhub.io/api/news?id=63c7187af8f8050b9f2c5293064471c6f77833a43dcbe715d36e6ca41d95f138"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
    "summary": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
    "url": "https://finnhub.io/api/news?id=af2aafb0cf42b97bac23331ec68d797ee9e274d8927b39712211af92d4fdb47c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752483060,
      "headline": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
      "id": 135948893,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
      "url": "https://finnhub.io/api/news?id=af2aafb0cf42b97bac23331ec68d797ee9e274d8927b39712211af92d4fdb47c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : Statement on New WHO Implementation and Testing Guidelines for Twice-Yearly Lenacapavir for HIV Prevention",
    "summary": "Foster City, Calif., July 14, 2025 - The World Health Organization today issued new guidelines for the use of twice-yearly lenacapavir as pre-exposure prophylaxis for HIV prevention, as well as new...",
    "url": "https://finnhub.io/api/news?id=16e96c4f5278376e9fff022cf67faa5fee44651ea6198d106ee8246759c8de74",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752482046,
      "headline": "Gilead Sciences : Statement on New WHO Implementation and Testing Guidelines for Twice-Yearly Lenacapavir for HIV Prevention",
      "id": 135923927,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Foster City, Calif., July 14, 2025 - The World Health Organization today issued new guidelines for the use of twice-yearly lenacapavir as pre-exposure prophylaxis for HIV prevention, as well as new...",
      "url": "https://finnhub.io/api/news?id=16e96c4f5278376e9fff022cf67faa5fee44651ea6198d106ee8246759c8de74"
    }
  },
  {
    "ts": null,
    "headline": "Uganda Among First to Benefit From Breakthrough HIV Prevention Drug",
    "summary": "Thanks to a landmark deal announced on July 9 by the Global Fund, Uganda is expected to be among the first countries in sub-Saharan Africa to get access to Lenacapavir, a revolutionary new drug that...",
    "url": "https://finnhub.io/api/news?id=a32a607d0a7d1cbfbc9d7b480b5317a1c82bc3b49f79bf9d0c58dbbc82ca5b13",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752476767,
      "headline": "Uganda Among First to Benefit From Breakthrough HIV Prevention Drug",
      "id": 135922110,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Thanks to a landmark deal announced on July 9 by the Global Fund, Uganda is expected to be among the first countries in sub-Saharan Africa to get access to Lenacapavir, a revolutionary new drug that...",
      "url": "https://finnhub.io/api/news?id=a32a607d0a7d1cbfbc9d7b480b5317a1c82bc3b49f79bf9d0c58dbbc82ca5b13"
    }
  },
  {
    "ts": null,
    "headline": "WHO recommends Gilead's twice-yearly injection for HIV prevention",
    "summary": "The World Health Organization onMonday recommended Gilead's lenacapavir, atwice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International...",
    "url": "https://finnhub.io/api/news?id=d5d99ff93d66e77941665cc7f46b06c649878e940df213097fc290ac8b27429f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752471398,
      "headline": "WHO recommends Gilead's twice-yearly injection for HIV prevention",
      "id": 135920531,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "The World Health Organization onMonday recommended Gilead's lenacapavir, atwice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International...",
      "url": "https://finnhub.io/api/news?id=d5d99ff93d66e77941665cc7f46b06c649878e940df213097fc290ac8b27429f"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Ready to Rebound. 3 to Watch Now.",
    "summary": "Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.  Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms.  Notable billion-dollar deals in the past two months include the acquisition of  Verona Pharma  by Merck,  Sanofi’s   buyout of  Blueprint Medicines  and  Eli Lilly’s   purchase of  Verve Therapeutics  In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.",
    "url": "https://finnhub.io/api/news?id=d921a7ea8f49b289f453f7c87799f0b573d2ce2df7c042968a8fea9c39cf3e8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752471000,
      "headline": "Biotech Stocks Are Ready to Rebound. 3 to Watch Now.",
      "id": 135917250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.  Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms.  Notable billion-dollar deals in the past two months include the acquisition of  Verona Pharma  by Merck,  Sanofi’s   buyout of  Blueprint Medicines  and  Eli Lilly’s   purchase of  Verve Therapeutics  In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.",
      "url": "https://finnhub.io/api/news?id=d921a7ea8f49b289f453f7c87799f0b573d2ce2df7c042968a8fea9c39cf3e8d"
    }
  },
  {
    "ts": null,
    "headline": "World Health Organization recommends injectable Lenacapavir for HIV prevention",
    "summary": "World Health Organization: WHO recommends injectable Lenacapavir for HIV prevention World Health Organization: recommends public health approach to HIV testing using HIV rapid tests to support...",
    "url": "https://finnhub.io/api/news?id=65849ee875956a2d68b891598c35480cce9d144f602c64b98581e4696294d94d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752469510,
      "headline": "World Health Organization recommends injectable Lenacapavir for HIV prevention",
      "id": 135919881,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "World Health Organization: WHO recommends injectable Lenacapavir for HIV prevention World Health Organization: recommends public health approach to HIV testing using HIV rapid tests to support...",
      "url": "https://finnhub.io/api/news?id=65849ee875956a2d68b891598c35480cce9d144f602c64b98581e4696294d94d"
    }
  }
]